Choose a language and wait for the translated text.
Gland Pharma has announced the conclusion of a routine US Food and Drug Administration (USFDA) Good Manufacturing Practice (GMP) inspection at its VSEZ sterile oncology formulations facility and API facility in Visakhapatnam.
The inspection was conducted from August 24 to September 1, 2026, and concluded with zero Form 483 observations, the company said in a regulatory filing.
Gland Pharma said the inspection covered its sterile oncology formulations and API facilities at the VSEZ site.
The post Gland Pharma’s Visakhapatnam facilities clear USFDA inspection with zero observations appeared first on Express Pharma.
